Trial Profile
A Phase IIIb/IV Randomized, Double-Masked, Active Controlled, Dose-Ranging, Multi-Center Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 6 Weeks for 102 Weeks, to Pegaptanib Sodium Plus Photodynamic Therapy (PDT) With Visudyne, in Patients With Exudative Age-Related Macular Degeneration (AMD)
Status:
Discontinued
Phase of Trial:
Phase III/IV
Latest Information Update: 22 Jun 2014
Price :
$35
*
At a glance
- Drugs Pegaptanib (Primary) ; Verteporfin
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Eyetech Pharmaceuticals
- 21 Jun 2014 New trial record
- 12 Jan 2007